Evidence map›Paper›PMID 35979020›Full record

ArticleFrontiers in cardiovascular medicine2022

Editorial: Research reproducibility and preventing fraud.

Shizuka Uchida, Jun Yu, Michel Goldman, Reto Asmis, Xiaofeng Yang, Elena Aikawa, Christos Bourantas, Masanori Aikawa, Hendrik Tevaearai Stahel

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shizuka UchidaCenter for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Jun YuDepartment of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Michel GoldmanInstitute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles, Brussels, Belgium.
Reto AsmisDepartment of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, United States.
Xiaofeng YangDepartment of Cardiovascular Sciences, Centers for Metabolic Disease Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Elena AikawaDivision of Cardiovascular Medicine, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences and Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Christos BourantasInstitute of Cardiovascular Science, University College London, London, United Kingdom.
Masanori AikawaDivision of Cardiovascular Medicine, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences and Center for Excellence in Vascular Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Hendrik Tevaearai StahelBern University Hospital, University of Bern, Bern, Switzerland.

Funding

Molecular control of ischemia-induced tissue fibrosisR01HL153599 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YU, JUN · 2020 to 2023
$2.1M
NHLBI NIH HHS R01 HL153599
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

data reproducibilityfraud preventionjournalspredatory journalsstatistics

Identifiers

PMID35979020
PMCPMC9376614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.